ReviewTumour virus research2025
Oncolytic virus and immunogenic cell death in cancer therapy.
Review in Tumour virus research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Immunogenic cell death and tertiary lymphoid structures: bridging tumour cell death and immune organization.Nature reviews. Immunology · 2026Review
- Emerging and Re-Emerging Viral Pathogens in Oncolytic Virotherapy: A Comprehensive Review.Reviews in medical virology · 2026Review
- Oncolytic virus OHSV2 induces pyroptosis in bladder cancer cells via the TLR4/NLRP3/Caspase-1/GSDMD pathway.Molecular biomedicine · 2026Article
- Synergistic Oncolytic Effect of HSVtk- and IL-15Rα-Armed Vaccinia Viruses Inducing Systemic Antitumor Immunity.International journal of molecular sciences · 2026Article
- Cancer Vaccines in Genitourinary Malignancies: Current Advances and Future Directions.Vaccines · 2026Review
- Enhancing antitumor immunity through oncolytic viruses: advances in genetic engineering.Discover oncology · 2026Review
- Review
- The interplay between oncolytic viruses, Toll-like receptor signaling, and chemotherapy in overcoming tumor immune tolerance.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a promising cancer treatment strategy, oncolytic viruses (OVs) selectively replicate and kill tumor cells while sparing normal cells. They improve the tumor immunosuppressive microenvironment through multiple mechanisms, including direct infection, replication, and lysis of tumor cells-leading to the release of tumor-associated antigens (TAAs), chemokines, and cytokines, which in turn induce immunogenic cell death (ICD) and trigger sustained antitumor immune responses. Currently, while OVs have demonstrated therapeutic efficacy in multiple preclinical and clinical studies, their monotherapy fails to benefit a broad spectrum of cancer patients. Therefore, there remains a need to fully understand the biological mechanisms of OVs and optimize immunotherapeutic strategies to benefit more cancer patients and enhance therapeutic efficacy. In this review, we discuss how the immune responses induced by OVs maintain a balance between antiviral and antitumor immunity, as well as their unique characteristics in inducing ICD. In addition, we describe how to enhance the efficacy of cancer immunotherapy by combining OVs therapy with ICD inducers, aiming to provide valuable insights to guide the development of clinical OVs -based therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.